Rising Rates of Teenage E-cigarette Use in the US

Oct.20.2022
Rising Rates of Teenage E-cigarette Use in the US
Teenage e-cigarette use rises in the US, with 14.1% of high school students and 3.3% of middle school students using them. Experts warn of health risks.

The proportion of teenagers using e-cigarettes has increased once again, according to a report released by the US Centers for Disease Control and Prevention. The National Youth Tobacco Survey, led by the US Food and Drug Administration and the CDC, showed that 14.1% of high school students and 3.3% of middle school students reported using e-cigarettes or other vaping products in the recent past. These figures suggest that approximately 2.5 million middle and high school students in the US are now vaping. Experts are particularly concerned that over a quarter of students are using e-cigarettes on a daily basis.


Dr. Ramiro Fernandez, Assistant Professor at the Division of Thoracic Surgery under Dr. David J. Sugarbaker at the Michael E. DeBakey College of Medicine, states that while extensive long-term data on the effects of electronic cigarettes are lacking, we are aware of acute lung injuries associated with their use, known as EVALI or electronic cigarette-associated lung injury.


Patients with EVALI experience respiratory symptoms and signs, including shortness of breath and decreased oxygen levels. They may also develop severe diffuse inflammation in their lungs, which can lead to death," said Fernandez. As of February 2020, there have been 2,807 reported cases of hospitalization or death due to EVALI, with 68 confirmed deaths.


Most e-cigarettes contain nicotine. In fact, a study by the Centers for Disease Control and Prevention found that 99% of e-cigarettes sold in assessment locations in the US contained nicotine. Nicotine can harm the developing brains of adolescents, which do not fully mature until around age 25. Additionally, research shows that teenagers who use e-cigarettes are more likely to start smoking traditional cigarettes in the future.


Electronic cigarettes also contain other harmful substances, such as ultrafine particles that can be inhaled deep into the lungs, flavorings associated with serious lung diseases, heavy metals like nickel, tin, and lead, as well as other carcinogens.


According to the American Cancer Society, the aerosol in e-cigarettes contains addictive substances that can lead to lung disease, heart disease, and cancer. A study by Johns Hopkins University in October 2021 on the components of e-cigarettes shows that there are thousands of chemical components in e-cigarette products, many of which have not been identified. The research team identified a pesticide, three chemicals never before found in e-cigarettes, and two flavorings associated with respiratory irritation and potential toxicity.


Although some people believe that electronic cigarettes can help people quit smoking, they have not been approved by the Food and Drug Administration as an aid. To quit smoking, seek help from your doctor or other support services, such as the smoking cessation program at the Baylor College of Medicine's Chest Clinic. It is important to note that electronic cigarettes are harmful not only to young people but also to adults.


People need to know that electronic cigarettes are harmful to your health," Dr. Fernandez stated. "Although the long-term effects are still unclear, data shows noticeable risks to cardiovascular and lung health.


For more information and resources, please see Baylor College of Medicine's position paper on taking action to address the issue of youth smoking and vaping.


Author: Tiffany Harston, Assistant to the Michael E. DeBakey Surgical Communications at Baylor College of Medicine.


Statement:


This article is compiled from third-party information and is intended for industry professionals for informational and educational purposes only.


This article does not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the authenticity or accuracy of the article's content. The article's translation is only intended for internal industry exchange and research purposes.


Due to the limitations of the compiler's skills, the translated article may not express the same meaning as the original. Please refer to the original article for accuracy.


In regards to any domestic, Hong Kong/Macau/Taiwan-related, or foreign statements and positions, 2FIRSTS is fully aligned with the Chinese government.


The copyright of compiled information belongs to the original media and authors. If there is any infringement, please contact us for removal.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

China Tobacco Supply-Chain Leader Huabao’s Three-Way Transformation Takes Hold as Overseas Revenue Jumps 216%, Non-Flavor Businesses Reach 42.2% and the Company Expands Into Global Next-Generation Tobacco Supply Chains
China Tobacco Supply-Chain Leader Huabao’s Three-Way Transformation Takes Hold as Overseas Revenue Jumps 216%, Non-Flavor Businesses Reach 42.2% and the Company Expands Into Global Next-Generation Tobacco Supply Chains
Huabao’s H1 2026 results show the company advancing across three connected fronts: international expansion, entry into next-generation tobacco supply chains and diversification beyond its traditional tobacco-related base. Overseas revenue rose 216.08% to CNY 96.02 million, while non-flavor businesses reached 42.2% of total revenue. Huabao also said it had entered the supply chains of leading global tobacco customers, as its nutrition, food ingredient, fragrance and personal-care businesses gained ground in Europe, Southeast Asia, Australia and New Zealand. However, adjusted net profit increased only 2.78%, and next-generation tobacco revenue was not separately disclosed, showing that the transformation is reshaping revenue and customer exposure but has yet to translate fully into underlying earnings.
Aug.28
Snowplus Enters Japan’s FamilyMart Network With Zero-Nicotine NEO Line and Kishidan Campaign
Snowplus Enters Japan’s FamilyMart Network With Zero-Nicotine NEO Line and Kishidan Campaign
Snowplus distributor H&S said the zero-nicotine, zero-tar NEO vaping line will begin rolling out across FamilyMart stores in Japan from September 14, 2026, excluding some locations. The DASH line will also be sold at selected FamilyMart stores in southern Kyushu and Okinawa. Snowplus simultaneously named Japanese rock band Kishidan as a brand ambassador, combining convenience-store distribution with a broader consumer marketing push in Japan.
Sep.15
2Firsts On-Site | PMI Brings IQOS, ZYN, VEEV and Marlboro Together at Its “Boulevard” at InterTabac 2026
2Firsts On-Site | PMI Brings IQOS, ZYN, VEEV and Marlboro Together at Its “Boulevard” at InterTabac 2026
At InterTabac 2026 in Dortmund, PMI is presenting multiple brands and products along “The PMI Boulevard,” including IQOS, ZYN, VEEV and Marlboro. On-site images captured by 2Firsts show dedicated spaces including the IQOS Boutique, ZYN Café, PMI Gallery and Marlboro Office
Market
Sep.16 by 2Firsts Perspectives
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
Product | R.J. Reynolds Launches Four Flavored Vuse Pro Pods for Vuse Alto Devices in U.S.
Product | R.J. Reynolds Launches Four Flavored Vuse Pro Pods for Vuse Alto Devices in U.S.
R.J. Reynolds Vapor Company has introduced Vuse Pro prefilled pods in Peach, Berry, Watermelon and Fresh Mint in selected U.S. states. Vuse’s U.S. website says the pods are intended for use with existing Vuse Alto devices. Each contains 2.0 mL of e-liquid at 5.0% nicotine by weight, uses nicotine salts and is offered in two- and four-pod packs. Reynolds said the rollout includes mandatory ID scanning for every purchase, purchase limits, stronger retailer-accountability requirements and strict age-restricted marketing standards. The four pods have not received marketing authorization from the U.S. Food and Drug Administration.
Sep.10
JTI Liggett Puts U.S. Value Cigarette Brands in Spotlight at 2026 NACS Show
JTI Liggett Puts U.S. Value Cigarette Brands in Spotlight at 2026 NACS Show
At the 2026 NACS Show in Las Vegas, JTI Liggett highlighted its value-priced cigarette portfolio, including LD and Montego, following JT Group's acquisition of Vector Group. The company's U.S. business reported market share gains, with LD sales volume rising 32.6% in the first half of 2026. Meanwhile, Ploom was displayed separately at Altria's booth under an existing partnership. JTI Liggett booth staff told 2Firsts that the company had not yet launched nicotine pouch products in the United States.
EXPO
Oct.09